Thrombate Articles
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
Lundbeck launches ATryn in USA
7 May 2009
GTC pursuing legal action against LEO
23 March 2009
GTC Bio gains $1M ATryn milestone
16 March 2009
FDA panel gives nod to GTC's antithrombin
19 January 2009
GTC's 3rd-qtr net loss narrows to $6.1M
17 November 2008
FDA accepts Ovation's ATryn BLA filing
13 October 2008
FDA priority review for GTC's Atryn
15 September 2008
GTC completes BLA filing for ATryn
18 August 2008
GTC's ATryn granted orphan status by FDA
17 December 2007
FDA fast-track for GTC's ATryn
10 September 2007
ATryn introduced at ISTH conference
26 July 2007
MA for GTC Bio's ATryn goes to Leo
8 January 2007
GTC Biotech sees potential for antithrombin Ab
15 August 2005
Argatroban OKed for new use in USA
15 April 2002
rhATIII dropped for primary indication
8 February 2001
Orphan drug status for rhATIII
11 May 2000
Genzyme Transgenics' antithrombin III, signs deal with Alexion
13 January 2000
Genzyme to develop angiogenesis inhibitor
20 September 1999
Genzyme clones goats for ATIII production
29 April 1999
Aventis Pipeline Rich In Near-Term Prospects
10 December 1998
Genzyme Starts Pivotal Antithrombin III Trials
21 May 1998
GW Drops 546C88 for Septic Shock
30 April 1998
Argatroban In Acute Myocardial Infarction
8 April 1998
UK Launch For Refludan; Angina Filing By End-98?
19 March 1998
New Advances In The Treatment Of Sepsis?
9 October 1997
Genzyme Completes ATIII Trial
18 September 1997
Centeon Begins Largest Worldwide Sepsis Study
17 July 1997
First Animal Milk Compound Trials By Genzyme Transgenics
16 September 1996
Astra Strengthens R&D With Increased Spending
4 December 1995
US ANTITHROMBOSIS MARKET FORECASTS
27 June 1994
$7.7 MILL GENZYME TRANSGENICS JV
2 May 1994
RESEARCH AND INVESTMENT IN CARDIOLOGY
20 December 1993
HYUN DAI TO LICENSE NOVASTAN INJ
7 June 1993
SYNTHELABO GAINS NOVASTAN RIGHTS
25 January 1993
EC CPMP MEETING RELEASES SPC GUIDELINES
29 June 1992
Showing 1-40 of 40 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
